Burzynski Research Institute, Inc.
BZYR
Other OTC0.01
USD
- -
- -
CIK
0000724445
ISIN
US1231591058
CUSIP
123159105
Return %
Stock
S&P500
1Y
-58.06
26.53
3Y
-83.07
76.60
5Y
-68.29
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Stanislaw R. Burzynski
- Full Time Employees
- 1
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 9432 Katy Freeway Houston TX United States of America 77055
- IPO Date
- Jan 2, 1997
- CIK
- 0000724445
- Website
- burzynskiclinic.com
- Similar Companies
- Business
- Burzynski Research Institute, Inc. (BZYR) engages in the research, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the trade name Antineoplastons for the treatment of various cancers, including brain tumors such as gliomas and diffuse intrinsic brainstem gliomas; the company develops six natural and six synthetic formulations of Antineoplastons, with primary focus on intravenous A10 and AS2-1 injections used in Phase II clinical trials conducted at the Burzynski Clinic in Houston, Texas, and a planned Phase III trial under protocol BT-52 combining Antineoplastons with radiation therapy. Founded in 1984 and headquartered at 9432 Katy Freeway, Houston, Texas, the company operates as a biopharmaceutical research and development facility with administrative offices in Houston and research/production facilities in Stafford, Texas; it targets patients with rare cancers through FDA-reviewed investigational new drug application IND 43742, holds orphan drug designations for Antineoplastons A10 and AS2-1 in brainstem gliomas and gliomas, and maintains exclusive licensing rights in the United States and Canada under a May 22, 2023, New License Agreement with founder and majority shareholder Stanislaw R. Burzynski, M.D., Ph.D., covering four to five U.S. patents. The company funds operations through a renewed Research Funding Agreement with Dr. Burzynski, who provides cash contributions, covers FDA-related clinical trial expenses reported as additional paid-in capital, and supplies laboratory space; its IND 43742 remains under full clinical hold by the FDA since August 24, 2017, due to unresolved manufacturing deficiencies at S.R. Burzynski's facility, preventing new patient enrollment in Phase II or III trials such as BT-55 for diffuse intrinsic pontine glioma; recent amendments limit agreements to the U.S. and Canada, with increased research and development costs of approximately $804,000 for the nine months ended November 30, 2024, driven by FDA requests for personnel, facilities, equipment, and quality control.